CYTK Cytokinetics Inc

UBS⬇️ $CYTK's PT to $104, reiterated Buy and said -- We see CYTK as an attractive launch name (oHCM) that has the added benefit of diversification (nHCM) and potential removal of competitive overhang (EWTX). $EWTX $BMY TECX TENX AZN NVO BAAYRY UBS added—Similar to a number of other commercial biotech names (NBIX, AXSM, JAZZ, UTHR, INSM), CYTK has also underperformed recently as XBI pulled back. However, if interest-rate hike cycle is likely to drive further "risk-off" environment, we believe names like CYTK can outperform from current levels. In our view, Myqorzo will see continued sales inflection in 3Q which could point towards strong FY26/27 sales. Along with oHCM launch updates, we see multiple potentially positive catalysts on the horizon: 1) nHCM SNDA submission, 2) EDG-7500 Ph3 trial initiation (requiring echos); and 3) MAPLE/1L label expansion (PDUFA Nov. 14). We lower our PT to $104 (from $115), and reit our Buy rating.

$CYTK Slew of CV trial fails lately. It makes this asset much more valuable. BP needs to buy this.

William Blair🏁 $CYTK and said -- We are initiating coverage of Cytokinetics with an Outperform rating, and our DCF-based valuation is $101/share. $EWTX $BMY TECX TENX AZN NVO BAYRY William Blair added—Cytokinetics is a commercial-stage specialty cardiology company built around muscle biology and its first approved product, MYQORZO. Our CYTK call: We have conviction in a strong MYQORZO launch through 2027. Around mid-2027, we model nHCM approval, assuming priority review, adding ~100K addressable patients. We estimate 2032 sales of ~$3.74B.

$CYTK New ACACIA-HCM responder data is pretty broad. At 36 weeks, 53% on aficamten hit a clinical response in 3 or more of 5 domains, vs 13% on placebo. Safety still has a cost though. LVEF below 50% showed up in 10.5% on drug vs 0.8% on placebo, and heart failure serious events were 4.7% vs 1.2%, all during titration or before week 12. Company still plans to file the supplemental NDA for non-obstructive HCM this quarter.

$CYTK I seen a Bezinga wire article Friday that said wholesales are tracking double this quarter vs last .. " Cytokinetics, Incorporated’s (NASDAQ:CYTK) MYQORZO wholesale sales are tracking toward roughly $18 million for the third quarter, versus $8.9 million for the entire second quarter, according to B. Riley." I am not sure how whole sale relates to net product revenue but if we get 100% more sales that's going to be great.

$CYTK Why is the CEO and his team selling stock. Do they know something and not disclosing. Their selling is just non-stop. They have a good product to market. The management is sending wrong signals by selling the stock. Marketing is working to sell and product and selling the stock damages company reputation. On a serious note, is their something that CYTK not disclosing. This could become a possible SEC investigation if something is disclosed down a year. Or do they know something about the lawsuit with BMY. Is something fishy ?